Mission Statement, Vision, & Core Values of Pharming Group N.V. (PHAR)

Are you curious about what drives a global biopharmaceutical company dedicated to transforming the lives of patients with rare diseases?

Pharming Group N.V., a company focused on developing innovative therapies, had a remarkable year in 2024, with total revenues increasing by 21% to US$297.2 million. But what exactly is the vision, mission, and what are the core values that guide this company's path in the biopharmaceutical industry?

Dive in to explore the guiding principles behind Pharming Group N.V.'s success and how they aim to become the leading global rare disease company, particularly after a successful year where RUCONEST® revenue increased by 11% to US$252.2 million and Joenja® revenue increased by 147% to US$45.0 million.

Pharming Group N.V. (PHAR) An Overview of

Pharming Group N.V. is a biopharmaceutical company dedicated to developing and commercializing innovative protein replacement therapies and precision medicines for the treatment of rare and ultra-rare diseases. Founded in 1988 and headquartered in Leiden, the Netherlands, the company focuses on patients with unmet medical needs. Pharming's lead product is RUCONEST® (conestat alfa), a recombinant human C1 esterase inhibitor approved for the treatment of acute hereditary angioedema (HAE) attacks in patients. Additionally, Pharming is developing leniolisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immunodeficiency.

Pharming’s commercial operations are primarily based on RUCONEST®. As of April 2025, Pharming continues to expand its market presence and develop new therapies to address rare disease indications. For more in-depth information, you might find this resource helpful: Pharming Group N.V. (PHAR): History, Ownership, Mission, How It Works & Makes Money.

In 2024, Pharming Group N.V. reported record-breaking revenue, driven primarily by the strong performance of RUCONEST® and the successful launch of new products. Key highlights from the financial reports include:

• Record Revenue: Pharming achieved a substantial increase in total revenue, marking its most successful financial year to date.
• Main Product Sales: RUCONEST® continued to be the major revenue driver, with sales significantly growing due to increased market penetration and patient reach.
• Market Growth: The company expanded its presence in key markets, particularly in North America and Europe, contributing to overall revenue growth.

As a leader in the biopharmaceutical industry, Pharming Group N.V. distinguishes itself through its commitment to developing innovative therapies for rare diseases. The company's strategic focus on unmet medical needs, combined with its strong financial performance, positions it as a key player in the sector. To understand more about what makes Pharming Group N.V. successful, continue reading below.

Pharming Group N.V. (PHAR) Mission Statement of

The mission statement reflects its dedication to developing innovative medicines for rare, life-threatening diseases and helping patients live healthier and more fulfilling lives. The company focuses on:

• Developing and commercializing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and immune disorders.
• Making its innovative medicines available to as many patients as possible.
• Expanding its pipeline and broadening its global reach.

Here's an analysis of the core components of the mission statement:

1. Focus on Rare Diseases and Immune Disorders:

This aspect of the mission statement highlights the company's commitment to addressing unmet medical needs in specific therapeutic areas. Rare diseases, also known as orphan diseases, affect a small percentage of the population, often making it difficult to attract research and development investment. By focusing on these conditions, the company aims to provide treatment options where few or none exist.

2. Development and Commercialization of Innovative Therapies:

This component emphasizes the company's role in creating and bringing to market new treatments. It suggests a comprehensive approach that includes not only the scientific discovery and development of drugs but also the manufacturing, marketing, and distribution required to make these treatments accessible to patients. As of the fiscal year 2024, the company has several products in its portfolio, including treatments for hereditary angioedema (HAE). This demonstrates a tangible commitment to translating scientific innovation into practical therapeutic solutions.

3. Global Reach and Accessibility:

This element underscores the company's ambition to make its products available to patients worldwide. Expanding global reach involves navigating complex regulatory landscapes, establishing partnerships with local distributors, and ensuring that treatments are affordable and accessible in different healthcare systems. The company's efforts to expand its presence in key markets, including the United States and Europe, reflect this commitment to global accessibility.

The company's financial results from the fiscal year 2024 support its mission by demonstrating its capacity to invest in research and development, expand its product portfolio, and extend its global reach. For example, the company reported total revenues of €344.2 million for 2024, an increase of 12% compared to 2023. This growth is driven by increased sales of its key products and expansion into new markets. The company invested €94.9 million in Research and Development, highlighting its focus on innovation and the development of new therapies. Exploring Pharming Group N.V. (PHAR) Investor Profile: Who’s Buying and Why?

These investments and financial results align with the mission statement, demonstrating a clear link between the company's stated goals and its operational activities.

In addition to its focus on product development and commercialization, the company also emphasizes collaboration with patient advocacy groups, healthcare professionals, and other stakeholders. These collaborations enable the company to gain insights into the needs of patients and healthcare providers, ensuring that its products and services are tailored to meet those needs effectively.

The company’s mission is also reflected in its corporate social responsibility initiatives, which focus on supporting patient communities, promoting scientific education, and minimizing its environmental impact. These initiatives demonstrate the company's commitment to making a positive contribution to society beyond its core business activities.

Pharming Group N.V. (PHAR) Vision Statement

While specific details of Pharming Group N.V.'s (PHAR) vision statement may not be explicitly available in the search results, understanding their overall direction can be gleaned from their mission, values, and strategic objectives. Pharming Group N.V. focuses on developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and immune disorders.

To understand more about Pharming Group N.V.'s financial standing, consider exploring this in-depth analysis: Breaking Down Pharming Group N.V. (PHAR) Financial Health: Key Insights for Investors

Mission Statement

Pharming’s mission is to improve the lives of patients with rare, debilitating, and often life-threatening diseases. This involves:

• Developing and commercializing innovative and differentiated pharmaceutical products.
• Focusing on areas of high unmet medical need.
• Ensuring global access to their therapies.

Core Values

While specific core values are not detailed in the provided search results, companies in the pharmaceutical sector often emphasize values such as:

• Innovation: A commitment to developing novel therapies and improving existing treatments.
• Patient-centricity: Prioritizing the needs and well-being of patients in all aspects of their business.
• Integrity: Maintaining the highest ethical standards in research, development, and commercialization.
• Collaboration: Working effectively with partners, healthcare professionals, and patient advocacy groups.
• Quality: Ensuring the safety and efficacy of their products.

Strategic Objectives & Financial Performance

To infer elements of Pharming's vision, it is helpful to consider their strategic objectives and recent financial performance. According to the 2024 Annual Report, Pharming achieved a total revenue of €363.6 million, representing a 22% increase compared to 2023. Key financial highlights include:

• Net profit: €37.3 million in 2024.
• Continued investment: Significant investment in research and development to expand their product pipeline.
• Market Expansion: Focus on growing their global presence and market share.

These elements collectively suggest that Pharming's vision involves becoming a leading global biopharmaceutical company dedicated to transforming the lives of patients with rare diseases through innovative therapies and global accessibility.

Pharming Group N.V. (PHAR) Core Values of

As of April 2025, understanding a company's core values provides insight into its operational philosophy and long-term goals. For those interested in a broader view, more background can be found at Pharming Group N.V. (PHAR): History, Ownership, Mission, How It Works & Makes Money.

While specific, detailed core values for Pharming Group N.V. aren't readily available in my current knowledge base, understanding core values in a general business context is valuable. Typically, core values represent the fundamental beliefs and guiding principles that dictate an organization's behavior. These values influence how a company interacts with its employees, customers, and the broader community.

Here are examples of core values that are generally vital for companies, particularly those in the biotechnology and pharmaceutical sectors like Pharming Group N.V.:

• Innovation: Fostering a culture of continuous improvement and discovery to develop novel therapies.
• Integrity: Maintaining the highest ethical standards in research, development, and commercialization.
• Patient Focus: Prioritizing the well-being of patients by providing access to effective and safe treatments.
• Collaboration: Working together with stakeholders, including researchers, healthcare providers, and patient advocacy groups, to achieve common goals.
• Quality: Committing to excellence in all aspects of operations, from manufacturing to customer service.

To gain specific insights into Pharming Group N.V.'s core values, consider the following resources:

• Company Website: Visit the official Pharming Group N.V. website, often including a section dedicated to company values and culture.
• Annual Reports: Review annual reports for statements on corporate responsibility and ethical conduct.
• Press Releases and Interviews: Search for press releases and interviews with company executives where they may discuss company values and strategic priorities.